Research Article

The Frequency of Anti-Aquaporin-4 Ig G Antibody in Neuromyelitis Optica and Its Spectrum Disorders at a Single Tertiary Referral Center in Malaysia

Table 4

Showing the differences between Anti-AQP4 seropositive and seronegative cohorts.

Anti-AQP4 positiveAnti-AQP4 negative value, <0.05 is significant
DiagnosisNMORTMRON/MONMTMNMOSD—BrainNMORTMRON/MONMTMNMOSD—BrainAQP4 +ve/ valueAQP4 −ve/ value
inv at onsetinv at onset.

Gender
 Female37103/019733/2090.020.384
 Male110/003301/100
Race
 Malays1912/005713/2050.1210.935
 Chinese1771/017121/103
 Indians230/000100/000
 Bajaus000/000000/001
 Ibans000/000100/000
Blindness
 Yes2601/002500/2010.0030.044
 No (one/both eyes)12112/0110532/008
PTS
 Yes27100/015520/0020.0040.387
 No803/005312/003
Cord atrophy
 Yes2190/014310/0020.0560.299
 No1723/007422/006
Type of cord lesion
 Long Cont216019320/002 <0.0010.220
 Long Cont & Int40001300/000
 Long Linear93000000/000
 Long Linear & Int10000100/000
 Long Conti & Linear11000100/001
 SS21002210/002
Site of axial cord lesion
 Holocord194016420/004<0.00010.059
 Central Gray matter197005520/024
 Periphery of cord00000000/000
 Partial diameter of cord00001000/011
Site of cord lesion
 Cervical1131/007410/003<0.00010.116
 Thoracic520/001110/000
 Cervico-thoracic2260/003410/002
 Thoracolumbar000/001000/000
 Whole spine000/010000/000

Abbreviations: NMO: Neuromyelitis optica; NMOSD: neuromyelitis optica spectrum disorder; RON: Relapsing optic neuritis; RTM: Relapsing transverse myelitis, MON: Monophasic optic neuritis; MTM: Monophasic transverse myelitis; Anti-AQP4 antibody: Anti Aquaporin 4 antibody, PTS: paroxysmal tonic spasms; Long Cont: Longitudinally contiguous; Long Linear: Longitudinally Linear; Long Cont & Int: Longitudinally contiguous and interrupted; Long Linear & Int: Longitudinally linear and interrupted; Long Cont & Linear: Longitudinally contiguos and linear, SS: short segment.
Patients with no lesions were not included in the table.
*Multiple short segment lesions were left out of the table—only one patient in the seropositive group.
For parameters PTS, cord atrophy, type of cord lesion, site of axial cord lesion and site of cord lesion, only available data was included. Patients with no cord lesions and those with monofocal, monophasic demyelinating diseases with onset in the brain but atypical for MS or NMO and were seronegative were excluded and thus the total number of patients will not be 96.